Home | GSK US
Hear from Rizwan Khokhar, an inclusive leader at GSK's Zebulon location in North Carolina.
Careers | GSK US
At GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
Contact us - GSK
Contact us online at GSK for You. RRC - a reimbursement support program that helps patients and healthcare professionals in the US with coverage, coding and reimbursement issues for certain GSK products.
Internships and co-ops | GSK US
Gain more insight to GSK, the application process, and more by visiting Connectr.
Products - GSK US
We deliver over 1.5 million doses of our vaccines every day; and 4 out of 10 infants born each year receive at least one GSK vaccine. Our vaccines portfolio targets infectious diseases at every stage of life, helping to protect people from RSV, meningitis, shingles, flu, polio and many more.
GSK announces cap of $35 per month on U.S. patient out-of …
GSK today announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all of its asthma and chronic obstructive pulmonary disease (COPD) medicines,* the most prescribed portfolio of inhalers in the U.S. GSK is taking this action as part of its longstanding commitment to improving access to respiratory ...
GSK invests up to $800 million in Pennsylvania site, largest ...
Oct 24, 2024 · GSK plc (LSE/NYSE: GSK) today announced its largest U.S. manufacturing investment to date. The up to $800 million investment will bring state-of-the-art drug substance manufacturing and additional drug product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, along with over 200 new jobs.
Ojjaara (momelotinib) approved in the US as the first and only
Sep 15, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia), in adults with anemia.
Search jobs | GSK US
Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. Registered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG. GSK websites; GSK Global website; Locations selector; Global Behind the science; GSKPro for HCPs; ViiV Healthcare;
Oncology | GSK US
At GSK Oncology, we are leading the way to re-imagine improved ways of engaging with people with cancer and their loved ones. We have an opportunity to take an authentically human approach in our work with patients and their entire care team.